An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis
- 1 October 2001
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 28 (7) , 637-642
- https://doi.org/10.1038/sj.bmt.1703200
Abstract
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.Keywords
This publication has 14 references indexed in Scilit:
- Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)Bone Marrow Transplantation, 2000
- Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status reportBone Marrow Transplantation, 2000
- Long-Term Survival (10 Years or More) in 30 Patients With Primary AmyloidosisBlood, 1999
- Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic AmyloidosisJournal of Clinical Oncology, 1999
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsBritish Journal of Haematology, 1998
- Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 PatientsBlood, 1998
- The Systemic AmyloidosesNew England Journal of Medicine, 1997
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineNew England Journal of Medicine, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine onlyThe American Journal of Medicine, 1996